Results 81 to 90 of about 24,049 (149)

Cost-effectiveness of durvalumab plus tremelimumab in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer from the US healthcare sector’s and societal perspectives

Yena Gan, Fenghao Shi, He Zhu, Huangqianyu Li, Sheng Han, Duoduo Li   +5 more
openalex   +1 more source

Efficacy of Immune Checkpoint Inhibitors in the Treatment for Head and Neck Cancer Patients: A Systematic Review and Network Meta-Analysis. [PDF]

Oncol Res
Li J, Rahman NA, Mohamad S, Yang G, Zhao C.   +4 more
europepmc   +1 more source

Outcomes Following Treatment for Progression in Patients Treated with Durvalumab Consolidation in La-Nsclc

Margaret Stalker, Melina E. Marmarelis, Corey J. Langer, Roger B. Cohen, Aditi Singh, Charu Aggarwal, Lova Sun   +6 more
openalex   +1 more source

Supplementary Fig. S1 from Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial [PDF]

Juan Francisco Rodríguez-Moreno, Guillermo de Velasco, Carlos Álvarez-Fernández, Ricardo Collado, Ricardo Fernández, Sergio Vázquez, Juan Antonio Virizuela, Pablo Gajate, Albert Font, Núria Laínez, Elena Sevillano-Fernández, Osvaldo Graña‐Castro, Luis Beltrán, Rodrigo Madurga, Cristina Rodríguez‐Antona, Pedro Berraondo, Sergio Ruiz‐Llorente, Jesús García-Donás   +17 more
openalex   +1 more source

Cytokine release syndrome caused by dual immunotherapy with tremelimumab and durvalumab: A case report. [PDF]

Respir Med Case Rep
Ito T, Yoshimura S, Kanai O, Fujimoto N, Imakita T, Oi I, Fujita K, Tanizawa K.   +7 more
europepmc   +1 more source

IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors. [PDF]

Cancer Res Commun
Powderly J, Imbimbo M, Italiano A, Martin-Romano P, McKean M, Macarulla T, Castañón Alvarez E, Carneiro BA, Mager R, Barnhart V, Eck S, Murtomaki E, Loembé AB, He Y, Cooper ZA, Tu E, Fan C, Boyer Chamard A, Paturel C, Fraenkel PG, Hollebecque A.   +20 more
europepmc   +1 more source

Efficacy of Durvalumab-Tremelimumab Treatment in Combination With Locoregional Therapy in Unresectable Hepatocellular Carcinoma: A Preliminary Study. [PDF]

Cancer Diagn Progn
Ishikawa T, Sato R, Natsui H, Iwasawa T, Ogawa M, Kobayashi Y, Sato T, Yokoyama J, Honma T.   +8 more
europepmc   +1 more source

Bridging Knowledge Gaps in Small Cell Lung Cancer: Data, Challenges and Priorities. [PDF]

Curr Oncol
Catania C, Cascetta P, Russo A, Governini E, Bendoni M, Laffi A, Piloni I, Conforti F, Pala L, Cocorocchio E, Ceresoli G, Locatelli M, Laszlo D, Facella F, De Pas T.   +14 more
europepmc   +1 more source

Phase IV clinical trials for the treatment of non-small cell lung carcinoma (NSCLC): A systemic review from 2020-2025. [PDF]

Saudi Med J
Kariri YA, Alqasmi MH, Alqahtani BS.
europepmc   +1 more source

Durvalumab consolidation after chemoradiotherapy for locoregional recurrent non-small cell lung cancer. [PDF]

Mol Clin Oncol
Suminaga K, Yoshida H, Shima Y, Yoshida H, Hashimoto K, Ogimoto T, Hosoya K, Funazo T, Ajimizu H, Nomizo T, Yoneyama M, Kishi N, Ozasa H, Hirai T.   +13 more
europepmc   +1 more source